In the world of small-molecule generics, firms that move from developing off-patent medicines towards focusing on innovative drugs are sometimes described as “poacher turned gamekeeper,” reflecting the change in mindset that comes when moving from a position of targeting brands to defending them.
In the biologics arena, however, Amgen has done the opposite, with the originator branching out into the world of biosimilars and building up a major business in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?